Epigenetic Therapeutics Tune Therapeutics specializes in epi-therapeutic medicines using the TEMPO platform to precisely modulate gene expression without permanent DNA changes, presenting a compelling opportunity to partner on multi-gene epigenetic silencing or activation programs in oncology, liver diseases, and aging-related conditions.

Clinical Progress Recent Phase 1b/2a proof-of-concept data for TUNE-401 in Hepatitis B and upcoming clinical activities in Hong Kong indicate strong clinical momentum and potential for collaboration on biomarker-driven trials, companion diagnostics, and regional regulatory strategy support.

Strategic Funding With over 215 million in funding and a Series B of 175 million, Tune Therapeutics is structurally positioned to scale partnerships, contract research, and joint development ventures across translational programs and expanded indication sets.

Leadership and Network New CEO appointment and high-profile industry visibility at JPM and EASL reflect a growth trajectory and access to top-tier pharma and biotech networks that can accelerate licensing discussions, co-development deals, and strategic investments.

Market Position Operating in a competitive CRISPR and epigenome editing landscape with notable peers and sizable funding, Tune presents an opportunity to differentiate via multi-gene epigenetic tuning capabilities, enabling large-market potential across chronic diseases and cancer where durable, reversible modulation of gene expression is advantageous.